Survival outcomes. At a median follow-up of 44 months, 61 (74%) participants were alive, and 21 (26%) had died. (A) Kaplan-Meier (KM)-estimated 3-year DFS is 72.8% (95% CI, 62.8-82.7). (B) KM-estimated 3-year OS was 74.9% (95% CI, 65.3-84.5). In comparison, Study 8 outcomes were an estimated 3-year DFS of 82.7% (95% CI, 79.6-85.8) and a 3-year OS of 93.4% (95% CI, 91.3-95.4). D1 is day 1 of protocol treatment.